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Addressing preference heterogeneity in public
health policy by combining Cluster Analysis and
Multi-Criteria Decision Analysis: Proof of Method
Mette Kjer Kaltoft1, Robin Turner2, Michelle Cunich3, Glenn Salkeld4, Jesper Bo Nielsen1 and Jack Dowie5*
Abstract
The use of subgroups based on biological-clinical and socio-demographic variables to deal with population
heterogeneity is well-established in public policy. The use of subgroups based on preferences is rare, except
when religion based, and controversial. If it were decided to treat subgroup preferences as valid determinants
of public policy, a transparent analytical procedure is needed. In this proof of method study we show how public
preferences could be incorporated into policy decisions in a way that respects both the multi-criterial nature of
those decisions, and the heterogeneity of the population in relation to the importance assigned to relevant criteria. It
involves combining Cluster Analysis (CA), to generate the subgroup sets of preferences, with Multi-Criteria Decision
Analysis (MCDA), to provide the policy framework into which the clustered preferences are entered. We employ three
techniques of CA to demonstrate that not only do different techniques produce different clusters, but that choosing
among techniques (as well as developing the MCDA structure) is an important task to be undertaken in implementing
the approach outlined in any specific policy context. Data for the illustrative, not substantive, application are from a
Randomized Controlled Trial of online decision aids for Australian men aged 40-69 years considering Prostate-specific
Antigen testing for prostate cancer.
We show that such analyses can provide policy-makers with insights into the criterion-specific needs of different
subgroups. Implementing CA and MCDA in combination to assist in the development of policies on important
health and community issues such as drug coverage, reimbursement, and screening programs, poses major
challenges -conceptual, methodological, ethical-political, and practical - but most are exposed by the techniques,
not created by them.
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Background
Most health care systems are currently under pressure
to reconcile the need to deliver services more efficiently
and provide more personalised health care. There are a
number of reasons for this pressure, including rapid
technological advances in medicine and communications,
aging populations, and economic crises. A key issue is
how population heterogeneity should be respected in pol-
icy decisions about health and community issues such as
drug coverage, reimbursement and screening. If fully indi-
vidualised public health care policies are impossible and
treating everyone as ‘average’ is unsatisfactory, then what
subgroupings represent the optimal compromise, and how
are they to be incorporated into public policy?
The case for using subgroups based on biological-clinical
and socio-demographic variables to address heterogeneity
is well-established in effectiveness research, with the main
issues being the statistical and clinical/policy significance
of such analyses. Subgrouping in cost-effectiveness is the
focus of ongoing debate, largely concerning the use of
particular variables for subgrouping rather than the
case for subgrouping in principle. Subgrouping based
on age and clinical history is widely employed in ana-
lyses for organisations determining cost-effectiveness
within specific settings, such as NICE in England and
Wales [1]. What remains controversial is the use of
subgrouping on the basis of individual preferences or
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values, moving beyond clustering based on such con-
cepts as patient satisfaction [2] or healthcare decision
making competencies and motivations [3].
The controversy is subdued in the case of most effect-
iveness research, where it is accepted that key determi-
nants of effectiveness, especially treatment adherence,
may be influenced by individual preferences independent
of the person’s biological-clinical or socio-demographic
characteristics [4]. Little concern has been shown when
the suggestion is made that clustered results from indi-
vidual decision analyses might be useful inputs into
group/policy decision making in some indirect and un-
specified way [5,6]. The question remains as to whether
the preferences of individual citizens, via preference-
based subgroups, should have a formal, direct role in
cost-effectiveness analysis and policy formation. This is
particularly important in relation to resource-consuming
decisions in collectively-funded public health services.
The case for acknowledging patient heterogeneity in
preferences has been convincingly made by Sculpher in
the context of menorrhagia therapy within the National
Health Service for England and Wales [7], following the
earlier work of Nease and Owens [8]. Sculpher con-
firmed that the two available interventions maximised
the patient-specific QALYs for one subgroup of women;
hence a strategy of offering treatment based on individ-
ual preferences at the point of care would, at least in
principle, be a cost-effective public policy even in the
collectively-funded system considered. This stimulated
discussion about the possibility of implementing fully in-
dividual patient preference-based QALYs [9,10], a route
subsequently explored by Basu and Meltzer [11-13]
when developing their Expected Value of Individualised
Care measure, and later by others [14-18].
However, none of these researchers seem enthusiastic
about treating subgroup preferences as fundamental
phenomena in driving health policy. Their implicit as-
sumption is either that individual or subgroup prefer-
ences can be reduced to, and treated as, epiphenomena,
i.e. as effectively being ‘caused’ by the biological-clinical
and/or socio-demographic characteristics of the person
or subgroup; or that preferences can be given policy
relevance only if interpreted and processed through their
associations with observable/verifiable objective charac-
teristics of persons. The one exception, which ‘proves
the rule’ - because subgrouping is not involved - is when
preferences are elicited at the population level and used
to produce a mean tariff applied to all individuals, as in
the EQ-5D tariff used in QALY-based analyses. If it were
decided to treat subgroup preferences as valid and inde-
pendent determinants of public policy, a transparent
analytical procedure will be needed.
The aim of this study is to present a procedure com-
bining two analytical techniques that have not, thus far,
featured in the debate: (i) Cluster Analysis (CA) which is
used to generate preference subgroups, and (ii) Multi-
Criteria Decision Analysis (MCDA) which provides the
explicit policy framework for including clustered prefer-
ences. Our study has an empirical basis, and the data are
from a large RCT about prostate cancer screening.
However, the focus is on providing a proof of method
for preference subgrouped public policy (via CA and
MCDA). Thus the results are presented as a practical
background to the discussion we hope to generate on
this crucial issue. Our illustration highlights a number of
issues that are likely to arise in any substantive
implementation.
Methods
The two techniques used in this study, Cluster Analysis
(CA) and Multi-Criteria Decision Analysis (MCDA), are
separately well-established. However, their combined use
in health-related research, as we propose, is innovative.
We could only locate one other application of the idea,
in production economics, where it was used to evaluate
e-commerce enterprises [19]. Before turning to these
techniques, we describe the data.
The data
For input into a public policy decision framed as a
MCDA we required individual preferences from a rep-
resentative sample of the population, expressed in the
form of importance weights for different criteria relat-
ing to the decision. We used data from one arm of a
Randomised Controlled Trial (RCT) of two online deci-
sion aids for Australian men aged 40-69 considering
Prostate-specific Antigen (PSA) testing for prostate
cancer, which was available and in the required format.1
Five criteria were provided in this arm of the trial:
LOSS OF LIFETIME: Avoid losing 5-10% of individual’s
remaining life expectancy.
NEEDLESS BIOPSY: Avoid having a needless biopsy.
URINARY PROBLEMS: Avoid urinary problems after
treatment for prostate cancer.
BOWEL PROBLEMS: Avoid bowel problems after
treatment for prostate cancer.
SEXUAL PROBLEMS: Avoid sexual problems
(impotence) after treatment for prostate cancer.
These criteria were developed in the context of an in-
dividual decision aid, but we believe they are a reason-
able set to explore as the effectiveness side of a public
policy issue in a proof of method.
The criteria selected were based on the findings of a
General Practitioner (GP) pilot study, a full account of
which has been presented [20]. GPs provided informa-
tion on the criteria we had included in the earlier ver-
sion of the decision aid and other factors they thought
were important for patients in making a decision about
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PSA testing, thereby supplementing findings from the
literature.
The RCT itself was based on a community sample of
1,970 men aged 40-69 years in 2011. Of these, 727 men
were allocated to the arm where the interactive decision
aid consisted of the five criteria outlined above.
The criterion weightings provided by respondent num-
ber 1526 can be seen in Figure 1, which displays the full
MCDA decision aid screen. Using this web-based deci-
sion aid template, the importance weightings were elic-
ited by respondents dragging the cursor to change the
bar lengths, dynamically normalised to add to 100%.
(MCDA as a technique does not elicit the inputs into it,
but in this case the template was used as the preference-
eliciting device.) The bottom Ratings panel contains the
evidence base for the analysis in the form of the perform-
ance rates for the two options on the five criteria [20].
These ratings were made available to the respondent after
their weightings had been elicited. (They were able to
change their weightings after seeing this data, but virtually
none did this and so it is the original weights which are
clustered.) The top panel displays the scores for the two
policy options, which result from combining the weight-
ings of respondent number 1526 with the evidence-based
ratings by way of a simple expected value calculation.
The only men excluded at survey entry were those
with diagnosed prostate cancer. There were no exclu-
sions for men ‘at risk’, so the 523 men whose preferences
were cluster analysed included those reporting a first de-
gree relative with prostate cancer (17%), or being unsure
thereof (9%). 204 of the original 727 respondents had
been previously excluded on the grounds that they had,
at two distinct points in the survey, clicked the same
point on a 10 point scale 8 times in a row as likely non-
serious responders. (Respondents were recruited by an
agency and received points for completion.)
The remaining 523 sets of criterion weights were ana-
lysed using CA to produce sets of subgroup means for
input into MCDAs of PSA testing.
We supply the above details to give the reader some
background to the importance weights being clustered,
but emphasise that the methods by which they were elic-
ited are largely irrelevant to our proof of method. Sets of
weights may be produced by diverse methods, including
Discrete Choice Experiments, and are suitable for clus-
tering so long as they produce a full set of attribute
weights for each individual.
Cluster analysis
CA and its various implementations are described in
many texts [21-23]. There are several implementation
packages, such as the R statistical package which was
used in this study [24]. CA has been widely used in sub-
grouping on the basis of observable characteristics, ran-
ging from types of gut bacteria at the cellular level [25]
to the human level, where it is proving useful in the def-
inition, diagnosis, and treatment of complex conditions,
such as back pain [26,27] and fibromyalgia [28]. Bass
and colleagues [29] used one of the main types of CA
(k-means) in pursuit of their aim of nudging Afro-
Americans towards colorectal cancer screening, identifying
three subgroups which they labelled ’Ready screeners’,
’Fearful avoiders’ and ‘Cautious screeners’.
Clustering
Three different techniques of CA were employed in this
study to demonstrate not only that different techniques
produce different clusters, but that choosing among
clustering techniques is an important task itself in
implementing the approach. We used Latent Class Ana-
lysis (MCLUST), Partitioning Around Medoids (PAMK)
and Hierarchical Agglomeration via Ward’s method
Figure 1 Annalisa MCDA screen with data for respondent 1526 in PSA decision aid trial.
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(HCLUST), presenting the solutions generated by
requesting 2, 3 and 4 clusters. The silhouette widths
cluster quality indicator introduced below was calculated
for solutions up to 9 clusters. The 2, 3 and 4 clusters in-
cluded the maximal widths for all three methods and it
was necessary to choose the same set for this compara-
tive analysis. In all cases we used the R statistical pack-
age noted in parentheses, which makes our analyses
accessible on an open source basis.
Latent Class Analysis (LCA) employs a model-based
approach in which probabilities of cluster membership
are estimated, and individuals are assigned to the cluster
for which their membership probability is highest.
In Partitioning methods the cluster membership of an
individual and hence the membership of clusters
changes throughout the process. The aim is to find a so-
lution that minimises the internal variance within clus-
ters relative to a specified centroid (e.g. the medoid, or
mean in the kmeans partitioning) and maximises the
distance between cluster centroids.
In Hierarchical Agglomeration methods, individuals
are progressively grouped in terms of their distance from
each other in n-dimensions, where n is the number of
criteria for clustering. Once assigned to a cluster they
remain in that cluster, while the process of allocating
unassigned individuals continues. The Ward’s method is
a special case, which assigns individuals to minimise the
internal distance of each cluster at that point in the
process.
Following the clustering analyses, and testing to see if
the cluster solutions provided groupings significantly dif-
ferent on the five criteria using ANOVA, we allocated
interpretive labels for each solution based on the weight
assigned to the highest weighted criterion, and assessed
the quality of the clusters produced by the alternative
solutions. The evaluation of cluster solutions, which in-
volves establishing the optimal number of clusters, as
well as the quality of the grouping, has been the subject
of continuing research since the early papers [30,31].
These issues are summarized [32].
It is widely acknowledged that cluster quality assess-
ment is inherently multi-dimensional. Raskutti and
Leckie (1999) suggest four criteria, but two of these four
- the compactness of the cluster (i.e. the mean intra-
cluster distance of observation from the centroid) and
the isolation of the clusters (i.e. the mean inter-cluster
distance) - are the ones most commonly used. They are
the basis of the silhouette coefficient measure we chose
[31]. Summary measures of cluster validity, and numer-
ical differences between clustering solutions on such
measures, must be interpreted in the light of the applica-
tion of the clusters [22]. Considerations of efficiency and
equity may lead to selection of a clustering solution
which is not highest, or even very highly rated, in terms
of purely statistical quality. In marketing, numerous
other criteria impact on the selection of a cluster solu-
tion. Statistical quality is only one of these. The ten cri-
teria below, collated from the marketing area [33], are
all potentially relevant in our case. We would omit only
criterion two, given our belief that preferences should be
elicited directly and separately from ‘objective’ character-
istics, in order not to treat people as a bundle of charac-
teristics. We have translated the marketing terms into
ones more appropriate for a health service setting:
1. Substantial: The subgroups are large enough to serve
efficiently.
2. Accessible: The subgroups can be effectively reached
and served, which requires them to be characterized
by means of observable variables.
3. Differentiable: The subgroups can be distinguished
conceptually and respond differently to different
policy-mix elements and programs.
4. Actionable: Effective programs can be formulated to
attract and serve the subgroups.
5. Stable: Only subgroups that are stable over time can
provide the necessary grounds for a successful
strategy.
6. Parsimonious: To be administratively meaningful,
only a small set of substantial clusters should be
identified.
7. Familiar: To ensure political acceptance, the
subgroups composition should be comprehensible.
8. Relevant: Subgroups should be relevant in respect of
the service’s competencies and objectives.
9. Compactness: Subgroups exhibit a high degree of
within-subgroup homogeneity and between-
subgroup heterogeneity.
10.Compatibility: Subgroup results meet other
administrative requirements.
Applying such criteria in a substantive application of
our method is a task for which we believe MCDA is
appropriate since it provides increased transparency in
terms of specification of the importance attached to
each criterion (the weightings) and the performance
ratings of the available options on the criteria, as well
as an explicit algorithm for combining the ratings and
weightings to produce an overall opinion (the scores).
Selecting a set of criteria and assigning importance
weightings to them is one part of the task approached
in this way. Arriving at ratings for how well each clus-
tering technique/solution performs on each of the se-
lected criteria is the second task. Integrating the
weightings and ratings into an overall evaluation of
each option is the final requirement, and in MCDA
this is normally done using the expected value
principle.
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We fully accept that whether or not MCDA is the
best, or an appropriate, approach to this task is itself a
multi-criterial decision, involving both performance
ratings and preferences.
Multi-criteria decision analysis
MCDA and its various forms are described and sur-
veyed in numerous texts [34-39] and there are many
examples of its use [1,37,40-45]. A large number of
software implementations exist, reflecting both varying
versions of MCDA and judgements about the extent
and type of complexity to be catered for, as well as the
time and cognitive resources required [46-49]. In the
illustrative analyses reported here we employ Annalisa©,
as used in the trial. Annalisa is an implementation of
the simple linear additive version of MCDA, in which
the scores for each option are produced by multiplying
the performance rates for the option on each of the cri-
teria by the respondent’s weights for those criteria, and
summing across criteria. Its one-screen-fits-all interface
was specifically developed to be less complex in both
development and delivery than the alternatives [20,49].
However, the selection of a software implementation of
MCDA, like the selection of the CA technique (and in-
deed software for implementing it), is not something
we wish to address on the present occasion. It would
be a crucial part of the policy-specific development
process.
The basic Annalisa screen (Figure 1) shows the
expected value Scores which result from combining the
evidenced-based Ratings for each policy Option on
each criteria with the respondent’s relative importance
Weightings for the criteria. The data are for respond-
ent number 1526 in the PSA trial from which our data
are drawn - see below. (The No PSA score is higher
for him, reflecting the importance Weightings he
gave.)
Translation into MCDA-based policy analysis
The results for each of the four cluster solutions within
the three CA techniques were fed into this MCDA tool,
and the subgroup scores for each policy calculated. Sub-
sequently, we conducted sensitivity analysis in relation
to the Loss of Lifetime criterion, to see what change in
the percentage rating for PSA vs. No PSA screening pol-
icy would be needed to bring each subgroup into equi-
poise, i.e. have equal scores for the two policy options.
This seemed the most interesting of the many possible
sensitivity analyses to undertake from a policy perspec-
tive, given it indicates the subgroup’s trade-offs of harms
with what is conventionally seen as the main potential
benefit (Loss of Lifetime).
Results
Clustering
The clustering solutions from the three cluster tech-
niques are shown in Table 1.2 The mean subgroup
weightings on the five criteria relevant to the PSA test
decision (Loss of Lifetime, Needless Biopsy, Urinary
Problems, Bowel Problems, and Sexual Problems) are
shown for each solution.
Differences in the clusters produced, given the fixed
criterion framing of the elicitation, are apparent. How-
ever, it is also clear that 3 broad preference patterns are
common to all three of the 4 cluster solutions, which are
the ones we focus on henceforth:
1. A relatively small subgroup of 10-11% ‘Very High
Lifers’, for whom Loss of Lifetime is almost all-
important with this criterion given 86-88% weight;
2. A relatively large subgroup of ‘Moderate Lifers’,
comprising 23-49% of the sample who give this
criterion 42-53% weight (and hence include
respondent 1526 in Figure 1);
3. The largest group of all (‘Equals’) at 33-63% of the
sample, who gave roughly equal weights to the five
criteria (including 14-22% weight to Loss of
Lifetime).
Setting these three subgroups apart, leaves a ‘Very
High Sexers’ group at 7% and 11% of the sample who
assigned 64% and 59% weights to the Sexual Problems
criterion in the PAM and Ward solutions, respectively.
They are replaced by ‘Moderate Biopsers’ at 4% with
53% weight assigned to Needless Biopsy in the LCA
solution.
On the basis of roughly averaging this data, a policy
based purely on Loss of Lifetime minimisation might
just attract majority support.
The statistical quality of the solutions, as approxi-
mated by silhouette width, varies from .26 to .44 (see
Table 1). A much reproduced scale would attach the
label ‘The structure is weak and could be artificial’ to
results in the .26-.5 range, but we can find no validation
of this scale. In any case we believe that, as made clear
earlier, clustering solutions should be evaluated by their
external real-world consequences, as well as their in-
ternal qualities.
We have confirmed that different techniques and solu-
tions produce different clusters. But also, that the result-
ing clusters are all capable of meaningful interpretations
based on the most prominent criterion (or lack of one).
However, to reiterate, we explicitly take no position on
the issue of the most appropriate clustering technique,
since this should be part of the policy development
process and reflect the application of criteria other than
statistical quality.
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4 1 327 62.5 0.24 0.22 0.15 0.20 0.20 0.23 Equals
2 53 10.1 0.64 0.88 0.02 0.04 0.03 0.03 Very High
Lifers
3 121 23.1 0.31 0.53 0.06 0.14 0.15 0.12 Moderate
Lifers
4 22 4.2 0.39 0.13 0.53 0.11 0.11 0.12 Moderate
Biopsers
0.31
3 1 407 77.8 0.29 0.27 0.13 0.19 0.19 0.21 Equals
2 92 17.6 0.60 0.78 0.03 0.07 0.06 0.06 Very High
Lifers
3 24 4.6 0.36 0.16 0.52 0.10 0.11 0.11 Moderate
Biopsers
0.35
2 1 493 94.3 0.25 0.36 0.11 0.17 0.17 0.18 Moderate
Lifers





4 1 270 51.6 0.33 0.19 0.18 0.22 0.22 0.19 Equals
2 59 11.3 0.63 0.87 0.03 0.04 0.03 0.03 Very High
Lifers
3 163 31.2 0.26 0.49 0.11 0.14 0.14 0.13 Moderate
Lifers
4 31 5.9 0.36 0.06 0.06 0.11 0.13 0.64 Very High
Sexers
0.35
3 1 301 57.6 0.27 0.18 0.17 0.21 0.21 0.24 Equals
2 59 11.3 0.63 0.87 0.03 0.04 0.03 0.03 Very High
Lifers
3 163 31.2 0.30 0.49 0.11 0.14 0.14 0.13 Moderate
Lifers
0.32
2 1 346 66.2 0.40 0.21 0.16 0.20 0.20 0.23 Equals





4 1 170 32.5 0.34 0.14 0.21 0.23 0.23 0.18 Equals
2 38 7.3 0.27 0.08 0.07 0.12 0.14 0.59 Very High
Sexers
3 60 11.5 0.68 0.86 0.03 0.04 0.04 0.03 Very High
Lifers
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Entering cluster weights into MCDAs
Pursuing our proof of method, the results from the 4
cluster solutions from the three techniques were now
inserted into MCDAs.
None of the preference-based subgroups produced by
any clustering solution favours a PSA screening policy.
There are various ways in which the complex set of re-
sults could be displayed, but we feel it most informative
to present just one type of sensitivity/threshold analysis.
Given the weight assigned by a subgroup to the Loss of
Lifetime criterion, what proportionate change in the ratings
for the two policy options on this criterion would result in
this subgroup being in policy equipoise (i.e. the option
scores being equal in its MCDA)?
The answers for all three of the 4 cluster solutions are
presented in Table 2, with Additional file 1: Tables S1,
S2 and S3 providing the full calculations, and S4 an illus-
tration of the calculation procedure.
The table confirms that the required changes are a
direct reflection of the subgroups' weights, with (in the
Ward solution), Very High Lifers (86% weight to Loss of
Lifetime) requiring a 1% improvement, and Moderate
Lifers (42% weight) an 8% improvement. The high (39%)
requirement for Equals reflects their low (14%) weight
for Loss of Lifetime, which is not much greater than that
of Very High Sexers. The requirement patterns in the
LCA and PAM solutions are similar. But the result for
Moderate Biopsers in LCA (95%) while it is consistent
with the 13% weight assigned to Lifetime Loss, is a use-
ful warning of the need to be cautious in selecting a so-
lution. It is from the one cluster that was not significant
in ANOVA (see Table 1 caption).
Age-stratified results
Following the exclusion of those participants ‘at risk’ of
prostate cancer or ‘unsure’ about their family history,
the sample for age-stratified clustering became 388. 156
were in their 40s, 135 in their 50s, and 97 in their 60s.
The same type of interpretable subgroups reappear
with different distributions (Additional file 1: Tables S5,
S6, S7), but with notably different thresholds on the Loss
of Lifetime criterion to produce equipoise. (Table 3)
(These were calculated in the same way as illustrated in
Additional file 1: Table S4.)
It seems a reasonable inference that age effects exist.
The proportions (%N) of both Moderate and Very High
Lifers increase progressively from younger to older at
the same time, as their equipoise requirement progres-
sively increases. This necessitates that the opposite hap-
pens for the proportions of the other subgroups, and we
indeed observe that Equals increase from 32% to 44%
moving from youngest to oldest groups. Their equipoise
requirement also rises dramatically, from near equipoise
for the 40s (0.4%) to 21.5% for the 60s. The residual sub-
group proportion increases from 8 % to 15%. In the 40s
and 50s it is the Very High Sexers, who are in virtual
equipoise in the 40s, but significantly divergent from it
in the 50s (14.4% requirement). However, in the 60s this
subgroup is replaced by Moderate Biopsers, a cluster
dominated by concern with needless testing.
Table 1 Mean cluster weights from 2, 3 and 4 cluster solutions using LCA, PAM and Ward methods (Continued)
4 255 48.8 0.17 0.42 0.12 0.15 0.16 0.15 Moderate
Lifers
0.29
3 1 208 39.8 0.22 0.13 0.19 0.21 0.21 0.26 Equals
2 60 11.5 0.68 0.86 0.03 0.04 0.04 0.03 Very High
Lifers
3 255 48.8 0.23 0.42 0.12 0.15 0.16 0.15 Moderate
Lifers
0.28
2 1 463 88.5 0.40 0.29 0.15 0.18 0.18 0.20 Moderate
Lifers
2 60 11.5 0.76 0.86 0.03 0.04 0.04 0.03 Very High
Lifers
0.44
Also shown are cluster sizes and statistical quality (as measured by average silhouette width). The bold numbers indicate the statistical quality of the cluster
solution. N.B. ANOVA showed all clusters to be significant at p < 0.05, except LCA 4/4 (Moderate Biopsers).
Table 2 Percentage increase in gap between relative Loss
of Lifetime performance ratings for PSA and No PSA
screening options needed to produce equipoise for each
4 cluster solution
Cluster LCA PAM Ward’s
Equals 19 25 39
Very High Lifers 1 1 1
Moderate Lifers 3 6 8
Very High Sexers … 56 43
Moderate Biopsers 95 … …
Kaltoft et al. Health Economics Review  (2015) 5:10 Page 7 of 11
All these variations have modest appeal in terms of
face validity, but any inferences need to be drawn with
caution, since the three clustering solutions are for dif-
ferent datasets (albeit from same responders), and so are
not directly comparable. These age effects are the com-
bined effect of different criterion performance ratings
for the age groups as well as different preference
patterns.
Discussion
This study presents an example of how public prefer-
ences could be incorporated into policy decisions
respecting both the multi-criterial nature of those
decisions and the heterogeneity of the population in re-
lation to their weightings. The various methodological
and practical issues to be addressed in implementing
such an approach are emphasised. Always to be deter-
mined are: the structure of the policy decision (options,
criteria in the MCDA); the choice of MCDA version and
implementation software; the choice of CA technique;
the choice of number of cluster solutions and measure
of cluster quality; and the trade-offs between statistical
quality and other criteria. It is the primary aim of this
paper to ensure that these issues are addressed transpar-
ently, rather than dealt with in an exclusively deliberative
process.
Objections to cluster analysis as an ‘unsupervised’
technique only to be used in abductive hypothesis gener-
ating – with the resulting clusters requiring ‘validation’
against some other criterion and insertion into a hypoth-
esis testing framework [27] – are of little relevance to
our approach. There is no gold standard against which
preference clusters can be compared. We have made
clear that regression of preference clusters on biological-
clinical or socio-demographic variables is inappropriate,
because we are in a policy/decision making practice con-
text, not a hypothesis-testing or scientific research-
driven one.
While the decision on which solution to adopt in the
presence of clustering differences requires consideration
of factors other than statistical quality, one thing should
not enter into analysis at the policy level in relation to
preference subgrouping regardless of the method used:
the characteristics of those individuals who move be-
tween clusters depending on the technique and solution.
Tracing such individual movements is feasible in all
software implementations of cluster analysis, but there
seems to be no conceptual justification for doing so. In
this sort of analysis an individual is simply a person ex-
pressing their preferences in the context of a particular
decision. It is vital they are not treated as a ‘bundle of
variables’. In some practice contexts it will be appropriate
to explore the statistical relationship between preference-
based subgroups and objective characteristics, typically via
regression analysis. Or to look forward and explore the re-
lationship with some future outcome or behavior, prob-
ably also via regression analysis. But we argue that neither
of these explorations is appropriate when it involves redu-
cing the preferences of a person, or group of persons, to a
set of predictive or predictor variables, since this under-
mines the fundamental personhood of the preference-
bearer [50].
A mini-debate provoked by a comment by Robinson
and Parkin on their paper [51,52] made clear that one
central issue is whether public or patient preferences are
appropriate. We are explicitly operating in the extra-
welfarist framework where stated public preferences over
outcomes are the inputs relevant for a subgrouped public
policy, not revealed patient choice of options. In a
collectively-funded health care system we take the view
that it is the preferences of members of the public, as
citizens which are the appropriate inputs into policy,
leaving patient preferences to be applied at the individual/
clinical level within the constraints set by community pol-
icy. Of course, there is nothing in the techniques them-
selves which rule out using patient preferences as inputs,
but the conflict of personal and public interest at, or near,
the point of care, poses major challenges to using those of
patients.
We do not address the cost side of policy making here,
instead concentrating on how subgroup preferences in
relation to effectiveness criteria could be incorporated
into Cost-effectiveness Analysis and public policies. As
emphasised by Claxton it is important that an MCDA-
based policy operating within a budget constraint re-
spects the existence of opportunity costs, ensuring that
Table 3 Percentage increase in gap between relative Loss of Lifetime performance ratings for PSA and No PSA
screening options needed to produce equipoise for each 4 cluster solution, by age group
40-49 years 50-59 years 60-69 years
% Change %N % Change %N % Change %N
Moderate Lifers 0.1 35 2.7 27 4.1 26
Very High Lifers 0.0 25 0.3 24 0.4 14
Equals 0.4 32 3.5 41 21.5 44
Very High Sexers 0.2 8 14.4 8 … …
Moderate Biopsers … … … … 45.4 15
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any net benefit foregone from the expansion of the
criteria on the effectiveness side (beyond QALYs)
should be taken into account [53].
In an extended MCDA framework it would be possible
to include options that fall within of the South-West
quadrant of the cost-effectiveness plane, i.e. are cost-
effective by being less effective, but proportionately
much cheaper, than the standard one [54]. And one
might include an explicit ‘Net effect on (generalised)
others’ criterion for individual respondents to weight. In
the extreme, this could be split into two on the basis of
the ‘just deserts’ criteria that emerges in most public sur-
veys. We are not advocating this, simply confirming that
moving to an MCDA-based public policy will make such
issues and their resolution more transparent.
A crucial finding in the Raskutti and Leckie paper, rep-
licating that of Macskassy, is that humans asked to clus-
ter the same data as a CA program, produce equivalent
variation in both the optimal number of clusters and
their content [32,55]. In other words, individual policy
makers engaging in subgrouping are unlikely to outper-
form a cluster solution, so the same discussion will be
needed if policy makers undertake the task.
Conclusions
In attempting to respect the heterogeneity of population
preferences in public policy, a subgroup approach of
some sort is inevitable. In this paper we illustrate how
two types of analysis might, in combination, represent a
viable approach. The implementation of Cluster Analysis
and Multi-Criteria Decision Analysis, individually and in
combination, poses major challenges - conceptual, meth-
odological, ethical-political, and practical. We outline
these challenges in the paper, stressing that most are
only exposed by these more analytical techniques, not
created by them. Alternative analytical or deliberative
approaches will face similar challenges, and any proper
evaluation must involve comparison of the approaches
in empirical practice, not simply against diverse sets of
normative principles. This is particularly important be-
cause computer technologies quickly expose the ‘digital
divide’, easily obscured in deliberative approaches. Such
unbiased comparative evaluation is the next item on the
research agenda.
The empirical results from our PSA screening example
are consistent with the trend away from advocacy of
PSA screening of asymptomatic men without a family
history of prostate cancer, based on both worries about
the test and preference considerations [56]. But the fact
that our results are in line with this observed trend
should not be misinterpreted. All we have sought to
show as proof of method, is that one can carry out ana-
lyses that identify the improvement in criterion perform-
ance (e.g. a superior test, less subsequent problems from
treatment) needed for a preference-based subgroup to
favour a screening policy.
Our finding of age-based preference subgrouping
raises the question of whether sub-subgrouping individual
preferences on bases such as age, sex, ethnicity, or religion
is consistent with truly person-centred public policy.
Endnotes
1 The trial from which the data come was approved by
the University of Sydney HREC (Protocol No.: 05-2011/
13712) on May 13 2011 and was included in the Australian
New Zealand Clinical Trials Registry (ANZCTR) on 6 July
2012 (ACTRN12612000723886) (https://www.anzctr.org.au/
Trial/Registration/TrialReview.aspx?id=343044).
2 An early version of this paper was presented in a
poster at the Lancet Public Health Science conference in
November 2013 [57]. This contains links which will
enable the reader to engage in interactive exploration of
the data in a downloadable spreadsheet and to explore
the survey as seen by a respondent.
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